Author

Petronela Weisova

Observed name: Petronela Weisová

Institution: Valneva (Austria)

Observed institution: Valneva (Austria)

ORCID: 0000-0003-2516-1399

Observed ORCID: 0000-0003-2516-1399

OpenAlex ID: A5024022174

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

2022 · Rajeka Lazarus, Benedicte Querton, et al. · The Lancet Infectious Diseases · 51

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

2023 · Christian Taucher, Rajeka Lazarus, et al. · Journal of Infection · 17

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil

2025 · Vera Buerger, Andrea Pfeiffer, et al. · The Lancet Infectious Diseases · 9

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial

2026 · Petronela Weisová, Susanne Scheiblauer, et al. · Nature Medicine · 3

Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator

2022 · Rajeka Lazarus, Benedicte Querton, et al. · SSRN Electronic Journal · 1

Works count: 5

Citation count: 81

H-index: 3

I10-index: 2